Compare Mesoblast Limited (MESO) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Stanley Black & Decker, Inc. — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Stanley Black & Decker, Inc. trades at $88.41 (market cap $13.60B). The key difference: Stanley Black & Decker, Inc. is far larger — about 6.3× Mesoblast Limited's market cap, and Stanley Black & Decker, Inc. pays a 3.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SWK | |
|---|---|---|
Market Cap | $2.17B | $13.60B |
Sector | Technology | — |
52-Week High | $20.96 | $94.12 |
52-Week Low | $12.88 | $62.12 |
Enterprise Value | $2.17B | $19.77B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Stanley Black & Decker (SWK) trades at $87.52, down 2.94% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company has beaten earnings estimates for the last three quarters, with Q2 2026 results expected soon. Revenue has stabilized around $15.1B in 2025, while net income improved to $402M. The stock carries a P/E of 36.95 and a dividend yield supported by recent payouts.
SWK shows operational resilience with consistent cash flow and debt reduction, but faces headwinds in Tools & Outdoor demand. Analyst sentiment is mixed with a consensus hold rating; the stock offers value and momentum potential amid ongoing cost-saving initiatives and aerospace growth, though high debt and consumer weakness pose risks to near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
